Popular

• 

  RestartResume

  Treating Mild Cognitive Impairment in Alzheimer’s Disease: A Therapy’s 2-Way MOA

  Medical Industry Feature

  Treating Mild Cognitive Impairment in Alzheimer’s Disease: A Therapy’s 2-Way MOA

• 

  RestartResume

  Diagnosing IBS-C: From Clinical Clues to Confident Calls

  Clinician's Roundtable

  Diagnosing IBS-C: From Clinical Clues to Confident Calls

  • 

    

    Darren Brenner, MD

    Peer

  • 

    

    Kyle Staller, MD, MPH

    Peer

• 

  RestartResume

  Neuroplasticity: A Potential Target for the Treatment of Depression

  Medical Industry Feature

  Neuroplasticity: A Potential Target for the Treatment of Depression

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

    Peer

  • 

    

    Madhukar H. Trivedi, MD

    Peer

• 

  RestartResume

  Anti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation 

  Medical Industry Feature

  Anti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation 

  • 

    

    Marwan Sabbagh, MD, FAAN, CCR

    Peer

  • 

    

    Cara Leahy, DO

    Peer

  • 

    

    David Weisman, MD

    Peer

• 

  RestartResume

  Living with Psoriatic Arthritis: A Doctor-Patient Conversation

  Medical Industry Feature

  Living with Psoriatic Arthritis: A Doctor-Patient Conversation

  • 

    

    Elizabeth Perkins, MD

    Peer

  • 

    

    Dawn Carter

    Peer

• 

  RestartResume

  Bridging the Gap in AYA Cure Rates

  Medical Industry Feature

  Bridging the Gap in AYA Cure Rates

  • 

    

    Ibrahim Aldoss, MD

    Peer

• 

  RestartResume

  Agitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice

  Medical Industry Feature

  Agitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

    Peer

  • 

    

    George Grossberg, MD

    Peer

  • 

    

    Angela Sanford, MD, CMD

    Peer

• 

  RestartResume

  Gene Therapy, the Future of Eye Care?

  Medical Industry Feature

  Gene Therapy, the Future of Eye Care?

  • 

    

    Courtney Crawford, MD, FACS

    Peer

  • 

    

    Raj Maturi, MD

    Peer

• 

  RestartResume

  Targeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach

  Medical Industry Feature

  Targeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach

• 

  RestartResume

  Tau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers

  Medical Industry Feature

  Tau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers

  • 

    

    Yuval Zabar, MD

    Peer

  • 

    

    Michelle Mielke, PhD

    Peer

  • 

    

    Henrik Zetterberg, MD, PhD

    Peer

• 

  RestartResume

  Breakthrough Technology Improves Concussion Assessment and Player Safety

  Medical Industry Feature

  Breakthrough Technology Improves Concussion Assessment and Player Safety

  • 

    

    Thomas S. Bottiglieri, DO

    Peer

• 

  RestartResume

  The Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy

  Medical Industry Feature

  The Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy

  • 

    

    Edgar V. Lerma, MD, FACP, FASN, FPSN (Hon)

    Peer

  • 

    

    Luis E. Vélez, MD

    Peer

• 

  RestartResume

  Improving Outcomes and Reducing Delays in Orthopedic Surgery

  Medical Industry Feature

  Improving Outcomes and Reducing Delays in Orthopedic Surgery

  • 

    

    Jennifer Caudle, DO, FACOFP

    Peer

  • 

    

    Jesse Pines, MD, MBA, MSCE

    Peer

• 

  RestartResume

  Early Referral in PMR Management and the Impact on Outcomes

  Medical Industry Feature

  Early Referral in PMR Management and the Impact on Outcomes

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

    Peer

  • 

    

    Amar Majjhoo, MD

    Peer

  • 

    

    Naureen Alim, MD

    Peer

• 

  RestartResume

  Expert Opinions on Characteristics of Patients With IgA Nephropathy (IgAN) at High Risk of Progression

  Medical Industry Feature

  Expert Opinions on Characteristics of Patients With IgA Nephropathy (IgAN) at High Risk of Progression

  • 

    

    Dana Rizk, MD

    Peer

  • 

    

    Carla Nester, MD

    Peer

  • 

    

    Sanjeev Sethi, MD, PhD

    Peer

  • 

    

    Leal Herlitz, MD

    Peer